July 9, 2008
NIH’s National Center For Research Resources Selects Collexis To Develop State of Science Analysis System
Collexis Holdings Inc. (OTCBB: CLXS), a leading developer of semantic and knowledge discovery software, announced today that the National Center for Research Resources (NCRR), of the National Institutes of Health (NIH), has chosen the company to develop a State of Science Analysis System to help better direct funding for biomedical technology research.
NCRR provides clinical and translational researchers with resources to understand, detect, treat and prevent a wide range of diseases. Because the answers to complex questions are not contained in single documents, NCRR must look across its entire grant portfolio to determine the best use of funding for resources. Traditional search technologies are not very useful for making this kind of analysis.Using ground-breaking technology from Collexis called Portfolio Analysis, NCRR will be able to compare the specific technologies it has funded to the state of science as represented in scientific journals and unfunded grant portfolios. This will enable NCRR to decide if it is funding research in the most promising technologies or overfunding some areas. It will also help identify gaps or "blind spots" where specific areas of research might be underfunded.
Collexis' Portfolio Analysis also provides time-based analysis so that NCRR can evaluate whether a funded area of research that looked promising several years ago has become less worthy over time. With this timeline analysis, NCRR will be equipped to make better funding decisions.
"We are pleased the NCRR has selected Collexis not only to mine their document collections, but also to map strategic knowledge that will improve their business." said Jon Lieberman, general manager, government and enterprise worldwide. "Portfolio Analysis goes beyond information retrieval to help organizations understand what is happening inside their organizations and compare it to competitors, partners and the world beyond their organization."
In addition to NCRR, a division of the NIH, Collexis is bringing its innovative technology to other research organizations and universities world-wide, including the Mayo Clinic Libraries; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Bristol-Myers Squibb; Lockheed Martin; World Health Organization; and U.S. Department of Defense.
About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of semantic search and knowledge discovery software is headquartered in Columbia, South Carolina (USA) with major operations in Cincinnati, Ohio, Geldermalsen, the Netherlands and Cologne, Germany. Collexis now offers the world's first pre-populated scientific social network for life science researchers, www.biomedexperts.com. Collexis' proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, Websites, emails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis' current clients in the public, private and academic sectors include the Mayo Clinic; Johns Hopkins University; Dana-Farber Cancer Institute, the University of California, San Francisco; the University of South Carolina; Erasmus University Library; Bristol-Myers Squibb; Lockheed Martin; the World Health Organization; Wellcome Trust; the National Institutes of Health; and the U.S. Department of Defense. Shares of Collexis common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, visit www.collexis.com.
NCRR provides clinical and translational researchers with the training and tools they need to understand, detect, treat, and prevent a wide range of diseases. This support enables discoveries that begin at a molecular and cellular level, move to animal-based studies and then are translated to patient-oriented clinical research, resulting in cures and treatments for both common and rare diseases. NCRR connects researchers with one another, as well as with patients and communities across the nation, to harness the power of shared resources and research. Transcending geographic boundaries and research disciplines, NCRR supports unique and essential research and resources that help to transform basic discoveries into improved human health. Together, the programs accelerate and enhance research along the entire continuum of biomedical science.
Disclaimer: National Institutes of Health (NIH) is not considered a supporter or partner of Collexis. Reference to NIH in the above shall not be construed as a Government endorsement nor does it obligate NIH to a position on or about the Collexis Software.
Some of the statements made in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and include known and unknown risks, uncertainties and other factors, many of which the company is unable to predict or control, that may cause the company's actual results or performance to differ materially from any future results or performance expressed or implied by such forward-looking statements. These statements involve risks and uncertainties, including risks and uncertainties associated with the company's collaboration with NCRR. These risks and uncertainties are in addition to other factors detailed from time to time in the company's filings with the SEC, including the section entitled "Risk Factors" in its transition report on Form 10-KSB for the period ended June 30, 2007, as amended. The company cautions investors that any forward-looking statements made by the company are not necessarily indicative of future performance. The company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.